The latest Global Burden of Disease analysis estimates that lead exposure contributes to 3.5 million deaths annually, including nearly 30% of coronary heart disease mortality worldwide. This is not a minor revision — it is a reframing.

Lead is no longer a peripheral concern. It is a central contributor to one of the leading causes of death. It does not act solely through blood pressure; it acts directly on the artery — promoting oxidative stress, impairing endothelial function, and accelerating atherosclerosis.

The bone-lead exposure-response curve documented here aligns with what we have seen in the natural experiment of leaded-gasoline removal: as exposure declined from over 130 ppb in 1976 to below 10 ppb today, hypertension prevalence fell from one in three American adults to one in five, and coronary heart disease mortality followed a parallel trajectory. We had conducted a massive, unplanned experiment, and only now are we recognizing what it was showing us.

The implication is straightforward: cumulative lead exposure remains a major, preventable contributor to global CVD mortality. Strengthened surveillance, regulation, and remediation are not optional.

The study's most consequential finding — an infection fatality rate of 0.17% — fed the belief that COVID was "no worse than the flu." That estimate proved low by a factor of four to eight, with implications that extended well beyond the paper itself.

Held against the nine "Gold Standard Science" criteria its senior author now promotes from his position at NIH, the study fails on multiple counts. The author group included economists, a hedge-fund manager, and lab scientists without prior work in antibody testing or seroepidemiology — but neither an infectious-disease epidemiologist nor an expert in antibody testing. Stanford-based investigators consulted experts who flagged concerns about the assay; those experts declined authorship.

Recruitment was conducted through Facebook advertisements despite explicit WHO guidance against advertisement-based recruitment for seroprevalence studies. The symptom screen omitted three of the six most common COVID symptoms (muscle aches, fatigue, headaches). Demographic adjustments amplified rather than corrected for self-selection bias. An email from the lead author's spouse promoting participation as a path to "peace of mind" and immunity confirmation is not mentioned in the paper.

Funding from David Neeleman, founder of JetBlue Airways, was disclosed only after external reporting; the paper's published Conflict of Interest statement reads "none." Peer review occurred at a journal where co-author Ioannidis served as an editor.

The concern is not that the study was wrong — many studies were wrong in early 2020. The concern is that the structure of the study made error likely, the direction of error predictable, and the response to those limitations insufficiently self-critical. More importantly, the senior author has positioned himself as an authority on Gold Standard Science despite the fact that his own most influential study fails to meet many of those criteria.